SES's O3b mPOWER System Receives Platinum Space Sustainability Rating
Article content
Article content
LUXEMBOURG — O3b mPOWER, SES's second-generation medium earth orbit (MEO) system, has been awarded the Platinum badge by the Space Sustainability Rating (SSR) Association. This is the highest possible SSR rating tier, and has been awarded to the O3b mPOWER constellation of 13 high-throughput and low-latency satellites, eight of which are already in orbit.
Article content
The O3b mPOWER mission was assessed across all phases: deployment, operations, and end-of-life disposal. The Platinum rating for O3b mPOWER was based on an in-depth analysis of more than 65 parameters, including: satellite count, orbital region, collision avoidance strategies, adherence to recognised design and operational standards, and SES's overall approach to data sharing and transparency. SES is the second operator to receive a Platinum rating from the SSR, and the sixth to be officially rated.
Article content
Rather than evaluating individual satellites in isolation, the SSR assesses the aggregate sustainability impact of the entire constellation and considers how satellites interact, operate collectively, and contribute to the broader space environment. This recognition indicates that the O3b mPOWER constellation demonstrates minimal impact on the orbital environment beyond what is necessary for mission success and reflects SES's strong commitment to sustainable space operations and adherence to internationally accepted best practices in space sustainability.
Article content
Prof. Jean-Paul Kneib, President of the SSR Association, Academic Director of EPFL Space Center and Head of the Laboratory of Astrophysics (LASTRO), said, 'The Space Sustainability Rating provides an independent benchmark to encourage transparency among space actors, promote best practices in space missions, and support the long-term preservation of the orbital environment. The Platinum rating awarded to the O3b mPOWER constellation reflects SES's strong alignment with the SSR's criteria across the full mission lifecycle. We celebrate this recognition for the O3b mPOWER constellation and SES's contribution to a safer, more responsible, and resilient satellite ecosystem. As the SSR continues to evolve, it aims to drive positive change across the space sector by highlighting leadership in space sustainability—such as that demonstrated by SES—and to encourage the global space community to make informed, sustainability-focused decisions.'
Article content
Milton Torres, Chief Technology Officer of SES, said, 'For 40 years, SES has been driving responsible best practices and developing new technologies, partnerships and solutions contributing to sustainable space. This Platinum badge not only highlights our leadership in sustainable space operations but also reinforces our commitment to responsible and innovative practices in the space industry, while supporting long-term space sustainability for all spacecraft operators.'
Article content
SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous earth orbit (GEO) fleet and medium earth orbit (MEO) constellation of satellites, offering a combination of global coverage and high-performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
Article content
The Space Sustainability Rating is a voluntary initiative launched by the World Economic Forum in 2016 and developed since 2018 by a consortium of academic and institutional partners including the European Space Agency (ESA), Massachusetts Institute of Technology (MIT), BryceTech, and the University of Texas at Austin. Created in consultation with industry, policy, and academic stakeholders, the SSR encourages responsible behavior in space by evaluating missions against a set of transparent sustainability criteria. The SSR provides a comprehensive framework for assessing the sustainability of space missions, identifying areas for improvement, and offering operators a chance to communicate their sustainability practices through independent, badge-based ratings: Bronze, Silver, Gold, or Platinum. Each SSR rating also includes actionable recommendations to guide operators in enhancing sustainability practices over time. This approach empowers responsible space actors to continuously evolve their mission strategies and set new benchmarks for space stewardship.
Article content
Article content
Article content
Article content
Contacts
Article content
For further information please contact:
Suzanne Ong
Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 hours ago
- Globe and Mail
Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY announced a strategic collaboration agreement with BioNTech BNTX. Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327 is a novel investigational bispecific antibody combining two complementary, validated mechanisms in oncology into a single molecule. Shares of BNTX surged on the deal announcement. Shares of Bristol Myers lost 12.8% year to date compared with the industry 's decline of 2.2%. More on BMY & BNTX Agreement Per the terms, BMY and BNTX will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. Both BMY and BNTX own the right to develop BNT327 independently in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BNTX will also receive $2 billion in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. Both the companies will jointly share development and manufacturing costs along with profits on an equal basis. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. It is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, including phase III studies with registrational potential evaluating BNT327 as first-line treatment in extensive stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). A phase III study evaluating the candidate in triple negative breast cancer (TNBC) is planned to start by the end of 2025. Data from ongoing trials (on a preliminary basis) underscore the potential for combining anti-PD-L1 and anti-VEGF-A – two well-established therapeutic targets – into a single molecule to deliver synergistic clinical benefits for patients across multiple tumor types. BMY Looks to Diversify Business BMY is depending on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. BMY earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years. BMY has experienced a few pipeline setbacks in recent months, which negatively impacted its share price. The late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy did not meet its dual primary endpoints. The top-line results from the phase III ARISE study on schizophrenia drug Cobenfy were also disappointing. The study is evaluating the efficacy and safety of the drug as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment. In November, Merck signed a deal with China-based LaNova Medicines for the latter's PD-1xVEGF targeting bispecific antibody candidate, LM-299. The latest entrant into this space is Pfizer PFE, which recently entered a multi-billion-dollar deal with Chinese biotech 3SBio for the latter's PD-1/VEGF bispecific antibody SSGJ-707. The deal is expected to be complete in third-quarter 2025. BMY's Zacks Rank & Stocks to Consider Bristol Myers currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Pfizer, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year. Pfizer's 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
Globe and Mail
5 hours ago
- Globe and Mail
Bachem Mourns the Loss of Company Founder Dr. H.C. Peter Grogg
Bubendorf, Switzerland--(Newsfile Corp. - June 3, 2025) - The founder and honorary chairman of Bachem (SIX: BANB) Peter Grogg, passed away on Monday, June 2, 2025, at the age of 83. Peter Grogg founded Bachem in 1971 and built the company from a two-person operation into the global market leader for the chemical synthesis of peptides. Peter Grogg was CEO of the company for over 30 years until 2002 and Chairman of the Board of Directors of Bachem Holding AG until 2012. His daughter Nicole Grogg Hötzer has served as Vice-Chairwoman of the Board since 2011. For his achievements and merits in the field of peptides, Peter Grogg was awarded an honorary doctorate by the University of Basel. Kuno Sommer, Chairman of the Board of Directors of Bachem: "With Peter Grogg, we have lost a great entrepreneur. His drive and values made Bachem an internationally successful company and have left a lasting mark on it. In doing so, he has written a chapter of Swiss economic history. On behalf of the Board of Directors, the Executive Committee, and all employees of Bachem, I would like to express our deepest condolences to his wife, his two children, and their families." About Bachem Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments. To view the source version of this press release, please visit
CTV News
6 hours ago
- CTV News
One of the world's most notorious pathogens has survived for centuries. Scientists say they now know why
Researchers have announced that they've discovered what allowed the bacterium Yersinia pestis, the cause of the Black Death, to keep its hosts alive longer. (BSIP/Universalvia CNN Newsource) One of the bleakest periods in medieval Europe was the plague pandemic known as the Black Death, which killed at least 25 million people in just five years. But the disease didn't stop there. The plague adapted to keep its hosts alive longer, so it could spread farther and keep infecting people for centuries, and researchers now say they've discovered how. The disease is caused by the bacterium Yersinia pestis, which has been circulating among human populations for at least 5,000 years. The pathogen has fueled three major plague pandemics since the first century AD, and though its deadliest years appear to be behind us, plague hasn't disappeared. Cases still occur a few times a year in Asia, South America and the United States and more commonly in parts of Africa, according to the Cleveland Clinic, and can be treated with antibiotics. Scientists are still searching for answers about how Y. pestis evolved and dispersed, but recent analysis of ancient and modern Y. pestis samples revealed how plague managed to persist among humans for hundreds of years after pandemic waves petered out. After an initial period of high infection rates and rapid mortality — killing infected people within three days — changes to just one gene in the bacterium produced new strains that were less deadly and more transmissible, according to research published Thursday in the journal Science. Those weakened strains eventually went extinct; the dominant lineage of today's Y. pestis is the deadlier variety, the study authors reported. However, these findings about historic instances of Y. pestis adaptation could provide important clues to help scientists and physicians manage modern plague outbreaks. Trio of outbreaks Plague's most common form is bubonic plague, which causes painful swelling in lymph nodes and spreads among people through bites from fleas hitchhiking on infected rats. An outbreak of bubonic plague from 1347 to 1352 in Europe famously killed about 30% to 50% of the continent's population. But the earliest known bubonic plague outbreak — the Plague of Justinian — took hold in the Mediterranean Basin and lasted from AD 541 to AD 544. Another plague outbreak emerged in China in the 1850s and sparked a major epidemic in 1894. Scientists view modern plague cases as part of this third pandemic. For the new study, scientists collected ancient samples of Y. pestis from human remains dating back to about 100 years after the appearance of the first and second plague pandemics, sampling remains from Denmark, Europe and Russia. After reconstructing the genomes of these plague strains, they compared them with older, ancient strains that dated back to the start of plague pandemics. The researchers also examined more than 2,700 genomes of modern plague samples from Asia, Africa, and North and South America. One of the study coauthors, Jennifer Klunk, is a product scientist at Daciel Arbor Biosciences, a biotechnology company in Michigan that provided synthetically created molecules for the experiments, but there was no financial gain associated with the research. The researchers found that their newly reconstructed genomes from 100 years into the first two plague pandemics had fewer copies of a gene called pla, which has been recognized for decades as one of the factors that made plague so deadly, according to the study's co-lead author Ravneet Sidhu, a doctoral student in the McMaster Ancient DNA Centre at McMaster University in Hamilton, Ont. Pla encodes an enzyme that interacts with host proteins, 'and one of the functions that it carries out is in breaking down blood clots,' Sidhu told CNN. This ability helps Y. pestis spread into the host's lymph nodes, where it replicates before attacking the rest of the body. 'Not every function of this gene is fully known,' Sidhu added. However, prior studies by other researchers linked pla to severity of illness caused by both bubonic and pneumonic plague — an airborne form of the disease that affects the lungs, she said. While the reconstructed strains showed fewer copies of the pla gene, the scientists were still uncertain whether that would directly affect how deadly the disease could be. So they tested strains of reduced-pla bubonic plague on mice, and found that survival rates for this type of plague were 10 to 20 percent higher in those experiment subjects than in mice infected with Y. pestis that had a normal amount of the pla gene. It also took the reconstructed bubonic strain about two days longer to kill its hosts. 'The paper presents a strong argument that depletion, but not total loss, of Pla (the enzyme produced by the pla gene) is part of the evolution of the plague pathogen and may help explain the decline of plague in the second pandemic commonly known as the Black Death,' said Dr. Deborah Anderson, a professor of veterinary pathobiology at the University of Missouri's College of Veterinary Medicine. Anderson, who was not involved in the new research, investigates the virulence of plague, and these findings could shed light on transmission patterns in modern cases, she told CNN in an email. 'Our laboratory studies the flea-rodent cycle and we have collaborators who conduct field research in areas that experience annual or occasional plague outbreaks in the wild,' Anderson said. 'There are nearly 300 rodent species that can transmit Yersinia pestis, and today, burrowing rodents such as prairie dogs or ground squirrels are considered key animal hosts that experience outbreaks of disease,' she added. 'After reading this paper, we will pay closer attention to Pla in the future to see if there continues to be a role for its expression in driving the explosive outbreaks of plague in the animal populations.' Yersinia pestis study Co-lead study author Ravneet Sidhu examines a human tooth at McMaster University's Ancient DNA Centre in Hamilton, Ont. (McMaster University via CNN Newsource) 'Epidemic burnout' Mathematical models suggested how this might have played out in human populations centuries ago, leading to an 'epidemic burnout' about 100 years after a bubonic plague outbreak. In a pandemic's early stages, infections were swift, and death came quickly for both rats and humans. Over time, as dense rat populations thinned out, selective pressures favored the emergence of a less deadly strain of Y. pestis, with fewer copies of the pla gene. Rat hosts infected with this new strain would have a little more time to carry the disease, potentially enabling them to infect more rats — and more people. 'They suggest a model that can be readily pursued in the laboratory that may help explain the spread of plague today in the wild,' Anderson said. These weaker strains of the disease eventually sputtered out and went extinct. In the modern samples, the researchers found just three examples of strains with reduced pla genes, from Vietnam: one from a human subject and two from black rats (Rattus rattus). 'We've been able to do this really cool interdisciplinary study between the modern and ancient data and marry these things that have been happening throughout (the plague's) long evolutionary history,' Sidhu said. 'It could be interesting to see how future researchers continue to try and bridge that gap between the modern third pandemic and those first and second ancient pandemics, to see other similarities. Because there aren't a lot of ancient pathogens that we have as much data on, as we do for Yersinia pestis.' One of the unusual features of plague pandemics is their persistence, and understanding how Y. pestis changed its infection patterns and survived over time could shed light on the adaptive patterns of modern pandemics such as Covid-19, she added. 'Even if we aren't experiencing it to the amount that we were in 2020 or 2021, the pathogen is in the background — still evolving and persisting.' By Mindy Weisberger, CNN
